Found: 81
Select item for more details and to access through your institution.
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm.
- Published in:
- Genes, Chromosomes & Cancer, 2010, v. 49, n. 4, p. 333, doi. 10.1002/gcc.20745
- By:
- Publication type:
- Article
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 11, p. E473, doi. 10.1002/ajh.24533
- By:
- Publication type:
- Article
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 10, p. 879, doi. 10.3390/cells13100879
- By:
- Publication type:
- Article
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
- Published in:
- Cell Death & Disease, 2022, v. 13, n. 11, p. 1, doi. 10.1038/s41419-022-05421-4
- By:
- Publication type:
- Article
Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
- Published in:
- Cytometry. Part B, 2017, v. 92, n. 2, p. 145, doi. 10.1002/cyto.b.21351
- By:
- Publication type:
- Article
A precision‐based exercise program for patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 930, doi. 10.1111/ejh.14106
- By:
- Publication type:
- Article
First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 2, p. 116, doi. 10.1111/ejh.13409
- By:
- Publication type:
- Article
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 2, p. 107, doi. 10.1111/ejh.13264
- By:
- Publication type:
- Article
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11507-9
- By:
- Publication type:
- Article
Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
- Published in:
- FEBS Journal, 2023, v. 290, n. 17, p. 4256, doi. 10.1111/febs.16805
- By:
- Publication type:
- Article
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 5, p. 1248, doi. 10.3390/ijms20051248
- By:
- Publication type:
- Article
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.
- Published in:
- Genes, Chromosomes & Cancer, 2005, v. 44, n. 2, p. 194, doi. 10.1002/gcc.20231
- By:
- Publication type:
- Article
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.
- Published in:
- Acta Neuropathologica, 2020, v. 139, n. 1, p. 175, doi. 10.1007/s00401-019-02067-z
- By:
- Publication type:
- Article
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma - Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.01676
- By:
- Publication type:
- Article
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
- Published in:
- Oncogene, 2005, v. 24, n. 21, p. 3512, doi. 10.1038/sj.onc.1208536
- By:
- Publication type:
- Article
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2023
- By:
- Publication type:
- journal article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S140, doi. 10.1016/S2152-2650(21)02315-6
- By:
- Publication type:
- Article
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S133, doi. 10.1016/S2152-2650(21)02304-1
- By:
- Publication type:
- Article
P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S110, doi. 10.1016/S2152-2650(21)02265-5
- By:
- Publication type:
- Article
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02194-7
- By:
- Publication type:
- Article
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S65, doi. 10.1016/S2152-2650(21)02183-2
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S5, doi. 10.1016/S2152-2650(21)02081-4
- By:
- Publication type:
- Article
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e286, doi. 10.1016/j.clml.2019.09.471
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed /refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e83, doi. 10.1016/j.clml.2019.09.133
- By:
- Publication type:
- Article
Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e43, doi. 10.1016/j.clml.2019.09.065
- By:
- Publication type:
- Article
Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S249, doi. 10.1016/j.clml.2018.07.149
- By:
- Publication type:
- Article
Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e119, doi. 10.1016/j.clml.2017.03.217
- By:
- Publication type:
- Article
A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e61, doi. 10.1016/j.clml.2017.03.112
- By:
- Publication type:
- Article
High Cut-off Hemodialysis Combined with Bortezomib-Based Therapy in Multiple Myeloma Patients with Severe Renal Impairment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e120, doi. 10.1016/j.clml.2017.03.218
- By:
- Publication type:
- Article
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 12, p. 6431, doi. 10.3390/ijms25126431
- By:
- Publication type:
- Article
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01126-3
- By:
- Publication type:
- Article
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00772-9
- By:
- Publication type:
- Article
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00390-3
- By:
- Publication type:
- Article
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
- Published in:
- British Journal of Haematology, 2007, v. 139, n. 1, p. 55, doi. 10.1111/j.1365-2141.2007.06747.x
- By:
- Publication type:
- Article
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 12, p. 2521, doi. 10.1007/s00432-017-2463-x
- By:
- Publication type:
- Article
Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [<sup>18</sup>F]FDG PET/CT predicts survival in multiple myeloma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 8, p. 2293, doi. 10.1007/s00259-024-06668-z
- By:
- Publication type:
- Article
Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 1117, doi. 10.1002/jha2.743
- By:
- Publication type:
- Article
Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 2, p. 307, doi. 10.1002/cam4.1283
- By:
- Publication type:
- Article
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1078725
- By:
- Publication type:
- Article
Extracellular vesicles mediate intercellular communication: Transfer of functionally active microRNAs by microvesicles into phagocytes.
- Published in:
- European Journal of Immunology, 2017, v. 47, n. 9, p. 1535, doi. 10.1002/eji.201646595
- By:
- Publication type:
- Article
Whole‐body magnetic resonance imaging plus serological follow‐up for early identification of progression in smouldering myeloma patients to prevent development of end‐organ damage.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 1, p. 65, doi. 10.1111/bjh.18232
- By:
- Publication type:
- Article
Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. 189, doi. 10.1111/bjh.16572
- By:
- Publication type:
- Article
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 4, p. 447, doi. 10.1111/bjh.16105
- By:
- Publication type:
- Article
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 981, doi. 10.1111/bjh.15680
- By:
- Publication type:
- Article
Multiple myeloma: patient outcomes in real-world practice.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 2, p. 252, doi. 10.1111/bjh.14213
- By:
- Publication type:
- Article
Multiple myeloma: practice patterns across Europe.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 1, p. 66, doi. 10.1111/bjh.14193
- By:
- Publication type:
- Article